Precision Biosciences Inc (DTIL): who owns it and who trades it
As of Nov 16, 2026, DTIL insiders reported 8 open-market sales worth $440K and 6 purchases worth $63.2K in the last 12 months, with 100% of the sale value made under pre-set 10b5-1 plans. The largest seller was Michael Amoroso (CEO), with $224K. 3 of the 50 famous funds we follow held it at their last quarter end.
Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.
At a glance
Who is buying and selling Precision Biosciences
From the latest filingsOverall: more buying than selling. Funds, insiders and famous investors mostly bought.
Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.
Who owns DTIL
94 funds and institutions reported DTIL shares worth $140M at the end of Q2 2026, about 72% of the company. The largest holder is Aberdeen Group plc with 9.0%.
Funds and institutions (13F) 72%Everyone else 28%
10 largest owners, by share of the company
Top 20 owners
| Owner | Shares | % of company | Value | Change since Q1 2026 |
|---|---|---|---|---|
| Aberdeen Group plc | 2.23M | 9.02% | $17.5M | No change |
| Bleichroeder LP | 2.02M | 8.16% | $15.9M | +21% |
| Octagon Capital Advisors LP | 1.35M | 5.46% | $10.6M | -40% |
| Boothbay Fund Management, LLC | 1.35M | 5.44% | $10.6M | +26% |
| BlackRock, Inc. | 1.17M | 4.74% | $9.2M | +487% |
| Vanguard Capital Management LLC | 1.12M | 4.51% | $8.8M | +23% |
| Lynx1 Capital Management LP | 950,466 | 3.84% | $7.5M | -4% |
| Driehaus Capital Management LLC | 946,707 | 3.83% | $7.4M | -5% |
| Empery Asset Management, LP | 776,093 | 3.14% | $6.1M | -61% |
| Affinity Asset Advisors, LLC | 646,576 | 2.61% | $5.1M | +8% |
| Geode Capital Management, LLC | 620,981 | 2.51% | $4.9M | +116% |
| Mackenzie Financial Corp | 480,997 | 1.95% | $3.8M | New |
| State Street Corp | 427,325 | 1.73% | $3.4M | +486% |
| Acadian Asset Management LLC | 305,759 | 1.24% | $2.4M | +583% |
| ArrowMark Colorado Holdings LLC | 274,140 | 1.11% | $2.2M | +53% |
| Corient Private Wealth LP | 245,058 | 0.99% | $1.9M | New |
| Two Sigma Investments, LP | 237,863 | 0.96% | $1.9M | -23% |
| Northern Trust Corp | 190,188 | 0.77% | $1.5M | +150% |
| JPMorgan Chase & Co | 180,452 | 0.73% | $1.4M | New |
| Vanguard Fiduciary Trust Co | 166,538 | 0.67% | $1.3M | +7% |
From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.
Insider trades
In the last 12 months, DTIL insiders reported $63.2K of open-market purchases and $440K of sales. 100% of the sale value was under a 10b5-1 plan, a schedule set up in advance.
Purchases and sales by month
Latest trades
| Date | Insider | Role | Type | Shares | Price | Value | Filing |
|---|---|---|---|---|---|---|---|
| Nov 10, 2026 | Dario Scimeca | Chief Legal Officer | Sale plan | 2,821 | $9.75 | $27.5K | Form 4 |
| Sep 28, 2026 | Stanley Frankel | Director | Purchase | 1,000 | $6.00 | $6K | Form 4 |
| Sep 25, 2026 | Melinda Brown | Director | Purchase | 1,135 | $6.27 | $7.1K | Form 4 |
| Sep 25, 2026 | Geno J Germano | Director | Purchase | 2,609 | $6.28 | $16.4K | Form 4 |
| Feb 18, 2026 | Michael Amoroso | CEO | Sale plan | 20,559 | $3.84 | $78.9K | Form 4 |
| Feb 18, 2026 | John Alexander Kelly | CFO | Sale plan | 8,149 | $3.84 | $31.3K | Form 4 |
| Feb 18, 2026 | Dario Scimeca | General Counsel and Secr | Sale plan | 4,925 | $3.84 | $18.9K | Form 4 |
| Jan 22, 2026 | Michael Amoroso | CEO | Sale plan | 34,799 | $4.17 | $145K | Form 4 |
| Jan 21, 2026 | Dario Scimeca | General Counsel and Secr | Sale plan | 8,854 | $4.03 | $35.7K | Form 4 |
| Jan 21, 2026 | John Alexander Kelly | CFO | Sale plan | 15,213 | $4.03 | $61.3K | Form 4 |
| Jan 21, 2026 | J. Jefferson Smith | Chief Research Officer | Sale plan | 10,200 | $4.03 | $41.1K | Form 4 |
| Dec 16, 2025 | Geno J Germano | Director | Purchase | 3,000 | $4.72 | $14.2K | Form 4 |
| Dec 16, 2025 | Stanley Frankel | Director | Purchase | 2,700 | $4.70 | $12.7K | Form 4 |
| Dec 15, 2025 | Melinda Brown | Director | Purchase | 1,381 | $4.97 | $6.9K | Form 4 |
Insiders by value traded
| Insider | Role | Bought | Sold | Last trade |
|---|---|---|---|---|
| Michael Amoroso | President and CEO, Director | – | $224K | Feb 18, 2026 |
| John Alexander Kelly | Chief Financial Officer | – | $92.6K | Feb 18, 2026 |
| Dario Scimeca | General Counsel and Secretary | – | $82.1K | Nov 10, 2026 |
| J. Jefferson Smith | Chief Research Officer | – | $41.1K | Jan 21, 2026 |
| Geno J Germano | Director | $30.5K | – | Sep 25, 2026 |
| Stanley Frankel | Director | $18.7K | – | Sep 28, 2026 |
| Melinda Brown | Director | $14K | – | Sep 25, 2026 |
What this data shows, and what it doesn't
- Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
- Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
- "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
- Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
- Filings are self-reported and can be amended. Each trade links to its original filing. Methodology
DTIL short interest
Moderate short interest. 7.5% of DTIL shares are sold short: about 1 share in 13. Over the last 12 reports the number of shares short went up 38%.
As a rough guide, under 5% is low, 5–10% is moderate, 10–20% is high and over 20% is very high.
As of Oct 30, 2026, 2.10M DTIL shares were sold short, 7.5% of the shares outstanding, down 11.0% from the report before. At the average daily volume of 199,360 shares, buying them all back would take about 10.5 trading days (days to cover).
Shares short, % of all shares
Days to cover
Every report
| Settlement date | Shares short | % of shares | Change | Avg daily volume | Days to cover |
|---|---|---|---|---|---|
| Oct 30, 2026 | 2.10M | 7.51% | -11% | 199,360 | 10.5 |
| Oct 15, 2026 | 2.36M | 8.54% | -6% | 251,947 | 9.3 |
| Sep 30, 2026 | 2.51M | 9.11% | +13% | 285,278 | 8.8 |
| Sep 15, 2026 | 2.22M | 8.06% | -12% | 210,717 | 10.6 |
| Aug 31, 2026 | 2.52M | 9.13% | +5% | 300,449 | 8.4 |
| Aug 14, 2026 | 2.40M | 8.70% | -17% | 264,571 | 9.1 |
| Jul 31, 2026 | 2.88M | 11.64% | +21% | 274,662 | 10.5 |
| Jul 15, 2026 | 2.38M | 9.64% | +4% | 662,442 | 3.6 |
| Jun 30, 2026 | 2.30M | 9.29% | +18% | 659,845 | 3.5 |
| Jun 15, 2026 | 1.94M | 7.86% | +16% | 358,409 | 5.4 |
| May 29, 2026 | 1.67M | 6.77% | +11% | 378,691 | 4.4 |
| May 15, 2026 | 1.51M | 6.13% | +7% | 231,988 | 6.5 |
Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks
Precision Biosciences company events
Precision Biosciences filed 16 reports on Form 8-K in the last 12 months, 2 of them about an important change (leadership). The latest was on Nov 9, 2026.
- Nov 9, 2026AnnouncementAs previously reported, on November 5, 2026, Precision BioSciences, Inc. entered into an underwriting agreement relating to the issuance and sale by the Company of 10,235,077 shares of its common stock, $0.000005 par value per share, at a price of $7.75 per share and, in lieu of Common Stock to… Filing
- Nov 6, 2026AnnouncementPrecision BioSciences, Inc. entered into an underwriting agreement with TD Securities (USA) LLC and Guggenheim Securities, LLC, as representatives of the several underwriters named therein, in connection with the offering, issuance and sale by the Company of 10,235,077 shares of its common stock… Filing
- Nov 5, 2026AnnouncementThe Company issued the HBV News Release announcing a late-breaking oral presentation at the American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2026. Filing
- Nov 3, 2026ResultsReleased financial results. Filing
- Aug 24, 2026AnnouncementThe Company issued a press release announcing the first patient has been dosed in its Phase 1/2 FUNCTION-DMD clinical trial evaluating PBGENE-DMD for the treatment of DMD. Item 9.01 Financial Statements and Exhibits. Filing
- Aug 6, 2026ResultsReleased financial results. Filing
- Jul 27, 2026LeadershipThe Board of Directors of Precision BioSciences, Inc. approved the appointment of a new Chief Operating Officer, the appointment of a new Chief Financial Officer, and other changes to its executive leadership team. Filing
- Jul 1, 2026AnnouncementIn its updated corporate deck and as previously reported, the Company announced PBGENE-HBV clinical highlights from its ELIMINATE-B study for chronic hepatitis B, including liver biopsy data demonstrated that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a 1-log… Filing
- Jun 16, 2026AgreementPrecision BioSciences, Inc. and Banc of California entered into a First Amendment to Amended and Restated Loan and Security Agreement.. The First Amendment amended the Amended and Restated Loan and Security Agreement, dated July 31, 2024, between the Company and Lender (as amended, including the… Filing
- May 27, 2026AnnouncementThe Company issued a press release to announce new and late-breaking PBGENE-HBV clinical data from the ELIMINATE-B study at EASL. Clinical highlights from the press release include: • New biopsy data demonstrate that PBGENE-HBV directly eliminated cccDNA through its primary mechanism leading to a… Filing
- May 26, 2026LeadershipPrecision BioSciences, Inc. held its annual meeting of stockholders. Filing
- May 5, 2026ResultsReleased financial results. Filing
- Mar 17, 2026AnnouncementShared information with investors. Filing
- Mar 12, 2026ResultsReleased financial results. Filing
- Feb 11, 2026AnnouncementThe Company issued a press release announcing it received FDA clearance of an IND for its PBGENE-DMD program for treatment of DMD. The FDA Study May Proceed notification enables initiation of clinical trial site activities for the FUNCTION-DMD Phase1/2 clinical trial. Filing
- Jan 13, 2026AnnouncementThe Company announced additional biopsy data in the ELIMINATE-B trial for PBGENE-HBV is expected in the first half of 2026. Filing
From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week
Precision Biosciences financials
Famous investors that hold DTIL
3 of the 50 well-known investors we track reported holding DTIL in their latest 13F filing. The largest position is Jim Simons's, worth $477K.
Position size
All holders
| Fund | Quarter | Shares | Value | Of portfolio | Change |
|---|---|---|---|---|---|
| Jim Simons · Renaissance Technologies | Q3 2026 | 76,263 | $477K | 0.0% | +11% |
| Ken Griffin · Citadel Advisors | Q3 2026 | 60,598 | $379K | 0.0% | -12% |
| Steve Cohen · Point72 Asset Management | Q3 2026 | 31,278 | $196K | 0.0% | +122% |
From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.
5%+ stakes filed in the last 120 days
Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 6 filings named DTIL in the last 120 days.
| Filed | Holder | Form | Stake |
|---|---|---|---|
| Nov 16, 2026 | Lynx1 Capital Management LP | 13G/A | 9.9% |
| Nov 16, 2026 | Lynx1 Capital Management LP | 13G/A | 9.9% |
| Nov 3, 2026 | Octagon Capital Advisors LP | 13G/A | 5.7% |
| Nov 3, 2026 | Octagon Capital Advisors LP | 13G/A | 5.7% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 5.0% |
| Oct 27, 2026 | BlackRock, Inc. | 13G | 5.0% |
Questions about Precision Biosciences Inc (DTIL) stock
Who owns the most DTIL stock?
The largest reported owner of Precision Biosciences Inc (DTIL) is Aberdeen Group plc, with 9.0% of the company. In total, 94 funds and institutions reported holding DTIL at the end of Q2 2026, together about 72% of the shares. See the largest owners.
Are DTIL insiders buying or selling?
In the last 12 months, DTIL insiders reported 6 open-market purchases worth $63.2K and 8 sales worth $440K. The latest trade was on Nov 10, 2026. See every trade.
What is the short interest in DTIL?
As of Oct 30, 2026, 2.10M DTIL shares were sold short, 7.5% of the shares outstanding, down 11.0% from the report before. At the average daily volume of 199,360 shares, buying them all back would take about 10.5 trading days (days to cover). See the history.
Which famous investors hold DTIL?
3 of the 50 well-known investors we track reported DTIL in their latest 13F filing, including Jim Simons, Ken Griffin, Steve Cohen. The largest position is worth $477K. See all holders.
Executive pay
Precision Biosciences's chief executive was paid a total of $2.2M for the year ended Dec 31, 2025, down 49% from $4.3M the year before. In the last 12 months, Precision Biosciences's executives and directors bought $63.2K of stock on the open market and sold $440K.
From the pay versus performance table in the company's annual proxy statement (DEF 14A), as the company reported it. If the chief executive changed during the year, the company reports each person separately and this shows one of them.
Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.